Insmed (MEX:INSM) EBIT: MXN-20,206 Mil (TTM As of Mar. 2026)


MEX:INSM Insmed Inc MEX:INSM
68 GF Score
Price MXN3,760.00
GF Value MXN5,773.42
! 4 Warning Signs
View Full Analysis

What is Insmed EBIT?

Insmed MEX:INSM 68 EBIT is MXN-20,206 Mil as of Mar. 2026. GuruFocus rates MEX:INSM with a GF Score™ of 68/100 and a GF Value™ of MXN5,773.42. The stock has 4 warning signs investors should review.

Insmed's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN-2,586 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-20,206 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Insmed's annualized ROC % for the quarter that ended in Mar. 2026 was -140.60%. Insmed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -372.66%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Insmed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.90%.


Insmed  (MEX:INSM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Insmed's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-14446.428 * ( 1 - 0% )/( (10707.594 + 9841.761)/ 2 )
=-14446.428/10274.6775
=-140.60 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=40774.952 - 6203.792 - ( 25748.997 - max(0, 8442.405 - 32305.971+25748.997))
=10707.594

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37433.415 - 5528.393 - ( 22063.261 - max(0, 6509.949 - 29089.865+22063.261))
=9841.761

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Insmed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-10343.412/( ( (2506.592 + max(-1654.706, 0)) + (2375.502 + max(669.085, 0)) )/ 2 )
=-10343.412/( ( 2506.592 + 3044.587 )/ 2 )
=-10343.412/2775.5895
=-372.66 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2536.229 + 2377.977 + 1642.768) - (6203.792 + 0 + 2007.888)
=-1654.706

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3219.829 + 2396.708 + 1410.067) - (5528.393 + 0 + 829.126)
=669.085

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Insmed's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-20205.873/412511.465
=-4.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insmed EBIT Related Terms


Insmed EBIT Historical Data

* Premium members only.

The historical data trend for Insmed's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed EBIT Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,161.06 -8,923.24 -11,385.58 -17,306.21 -21,501.87

Insmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,826.58 -5,665.22 -6,414.25 -5,540.55 -2,585.85

MEX:INSM vs INCY, BNTX, ROIV: EBIT Comparison

For the Biotechnology subindustry, Insmed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Insmed's EV-to-EBIT falls into.


MEX:INSM
68GF Score
Insmed Inc MEX:INSM
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-20,206 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-20,206 Mil mean?
Insmed (MEX:INSM) has a EBIT of MXN-20,206 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Insmed.
Is Insmed's EBIT too high?
Insmed's current EBIT is MXN-20,206 Mil. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's EBIT compare to INCY and BNTX?
Insmed's EBIT of MXN-20,206 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Insmed. Insmed's current EBIT is MXN-20,206 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current EBIT of MXN-20,206 Mil. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current EBIT is MXN-20,206 Mil. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Insmed (MEX:INSM), the current EBIT is MXN-20,206 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MEX:INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.

Key valuation signals for MEX:INSM:

  • EBIT: MXN-20,206 Mil
  • GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score

Get the complete analysis for MEX:INSM

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,760.00
Price
MXN5,773.42
GF Value